China Pharma Holdings, Inc. (CPHI)
Stock Price Chart
Key Info
| Market Cap | 20.58M |
| Revenue (ttm) | 10.98M |
| Net Income (ttm) | -20.40M |
| Shares Out | 43.58M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 27 |
| Last Price | $0.472 |
| Previous Close | $0.487 |
| Change ($) | -0.014 |
| Change (%) | -2.92% |
| Day's Open | 0.487 |
| Day's Range | 0.460 - 0.487 |
| Day's Volume | 490,377 |
| 52-Week Range | 0.222 - 1.400 |
More Stats
| Market Cap | 20.58M |
| Enterprise Value | 25.24M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 43.58M |
| Float | 21.94M |
| EPS (basic) | -0.48 |
| EPS (diluted) | -0.47 |
| FCF / Share | -0.05 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 100,308 |
| Short Ratio | 0.18 |
| Short % of Float | 0.46% |
| Beta | 0.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 1.87 |
| PB Ratio | 2.70 |
| Revenue | 10.98M |
| Operating Income | -20.15M |
| Net Income | -20.40M |
| Free Cash Flow | -2.32M |
| Net Cash | -4.66M |
| Net Cash / Share | -0.11 |
| Gross Margin | 13.49% |
| Operating Margin | -183.47% |
| Profit Margin | -185.80% |
| FCF Margin | -21.15% |
| ROA | -6.43% |
| ROE | -115.87% |
| ROIC | -133.20% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.92 | 12.33 | 13.21 | 15.57 | 20.35 | 22.13 | 32.81 | 54.51 | 81.17 | 74.39 |
| Revenue Growth | -11.41% | -6.67% | -15.15% | -23.49% | -8.05% | -32.53% | -39.81% | -32.85% | 9.11% | - |
| Gross Profit | 1.48 | 1.97 | 2.47 | 3.22 | 1.46 | 2.67 | -0.48 | 14.08 | 28.99 | 30.28 |
| Operating Income | -20.41 | -10.45 | -18.68 | -8.16 | -14.30 | -38.76 | -18.61 | 5.76 | 21.72 | 24.20 |
| Net Income | -20.70 | -10.75 | -19.28 | -9.18 | -15.41 | -39.55 | -20.01 | 4.62 | 19.27 | 23.41 |
| Shares Outstanding | 43.58 | 43.58 | 43.58 | 43.58 | 43.58 | 43.58 | 43.58 | 43.58 | 43.53 | 43.39 |
| Earnings Per Share | -0.48 | -0.25 | -0.44 | -0.21 | -0.35 | -0.91 | -0.46 | 0.11 | 0.44 | 0.54 |
| EPS Growth | - | - | - | - | - | - | - | -75% | -18.52% | - |
| Operating Cash Flow | 0.61 | 1.88 | 0.84 | 2.90 | 3.35 | 6.15 | 8.60 | 3.64 | 5.24 | 7.79 |
| Capital Expenditures | -0.14 | -0.05 | -0.14 | -0.19 | -0.69 | -5.13 | -18.79 | -1.77 | -0.35 | -10.52 |
| Free Cash Flow | 0.47 | 1.83 | 0.70 | 2.70 | 2.66 | 1.02 | -10.20 | 1.87 | 4.88 | -2.73 |
| Cash & Equivalents | 1.23 | 2.48 | 2.78 | 3.75 | 6.25 | 5.75 | 6.33 | 4.13 | 4.13 | 3.69 |
| Total Debt | 4.55 | 7.82 | 9.93 | 11.17 | 16.95 | 17.92 | 17.39 | 4.76 | 3.93 | 3.78 |
| Net Cash / Debt | -3.32 | -5.34 | -7.15 | -7.42 | -10.70 | -12.17 | -11.06 | -0.63 | 0.20 | -0.09 |
| Assets | 22.24 | 45.38 | 59.95 | 78.52 | 96.51 | 121 | 158 | 163 | 156 | 132 |
| Liabilities | 13.00 | 15.18 | 16.88 | 19.61 | 23.87 | 28.34 | 24.67 | 14.72 | 13.91 | 13.81 |
| Book Value | 9.24 | 30.20 | 43.07 | 58.91 | 72.64 | 92.74 | 133 | 149 | 142 | 118 |
Company Profile
Company Details
| Full Name | China Pharma Holdings, Inc. |
| Country | China |
| Employees | 228 |
| CEO | Zhi Lin Li |
Stock Information
| Ticker Symbol | CPHI |
| Stock Exchange | NYSE American |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSEAMERICAN: CPHI |
Description
China Pharma Holdings develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.